ASCO Annual Meeting

Reductions in severe oral mucositis across all intensity-modulated radiotherapy landmarks was observed with avasopasem treatment in patients with locally advanced, nonmetastatic head and neck cancer.

Therapy with brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine lead to a significant reduction in the risk of death vs doxorubicin, bleomycin, vinblastine, and dacarbazine, in patients with previously untreated stage III/IV classical Hodgkin lymphoma.

Treatment with the KRAS G12C inhibitor adagrasib showed a promising objective response rate and disease control rate in patients with previously treated KRAS G12C–mutated non–small cell lung cancer.

The use of pembrolizumab plus ramucirumab to treat non–small cell lung cancer in immune checkpoint inhibitor resistant patients showed better overall survival versus standard of care regimens in the Lung-MAP nonmatched phase 2 substudy S1800A.

Karen L. Reckamp, MD, explains the need for more treatment options for patients with non–small cell lung cancer who have been previously treated with immune checkpoint inhibitors and develop resistance.

The combination of nimotuzumab and gemcitabine extended overall survival in patients with KRAS wild-type advanced pancreatic cancer, especially in those who did not need surgery for obstruction of a pancreatic bile duct

According to a survey, some Black patients with metastatic breast cancer harbor distrust toward clinical trials, which has impacted the number of Black patients who participate.

After identifying a survival disparity among non-White Hispanic patients with pediatric neuroblastoma, investigators will next examine the interaction of survival and race, ethnicity, and poverty, acknowledging the intersectionality of these factors due to structural racism in the United States.

An updated analysis, presented at the 2021 ASCO Annual Meeting, showed encouraging signs for the combination of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.

Updated findings for belzutifan showed that with further follow-up, the hypoxia-inducible factor-2 alpha inhibitor continues to show significant clinical activity in patients with Von-Hippel Lindau–associated renal cell carcinoma treated in the frontline setting. Updated results from the phase 2 study.

Results of a single-arm phase 2 study of regorafenib plus nivolumab in patients with mismatch repair–proficient/microsatellite stable colorectal cancer found a discrepancy in efficacy between the Japanese and North American Population.

More the half of patients with metastatic renal cell carcinoma who received pembrolizumab in combination with cabozantinib had a response to the combination at the recommended phase 2 dose and tolerated treatment well.

Efficacy was improved with Lenvatinib plus pembrolizumab for patients with advanced renal cell carcinoma across evaluable International Metastatic RCC Database Consortium risk subgroups over sunitinib.

Second-line treatment with cetuximab in patients with metastatic colorectal cancer given after irinotecan or oxaliplatin-based regimen failure, KRAS mutational status and geographical region were associated with time on treatment, while body mass index and age were linked with overall survival.

In men with de novo metastatic castration-sensitive prostate cancer treated in the phase 3 PEACE-1 study, the addition of abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel improved radiographic progression-free surviva.

In patients with relapsed/refractory multiple myeloma, treatment with higher doses of subcutaneous elranatamab was found to be effective, according to findings from a phase 1 clinical trial.

Few patients required subsequent anticancer therapies with the combination of lenvatinib (Lenvima) plus everolimus versus sunitinib for advanced renal cell carcinoma

Sustained efficacy and durable responses was seen with Ciltacabtagene autoleucel, an investigational B-cell maturation antigen-directed CAR T-cell therapy, in heavily pretreated patients with relapsed/refractory multiple myeloma.

In patients with muscle-invasive bladder cancer combining transurethral resection of the bladder tumor with nivolumab and chemotherapy showed promise as a bladder-sparing treatment strategy.

A favorable safety profile and promising efficacy was seen with C-CAR066, a novel 2nd generation chimeric antigen receptor T-cell therapy targeting the CD20 antigen, in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma who failed with prior CD19 CAR T-cell therapy.

Updated analysis from the MonumentTAL-1 trial showed the benefits of the recommended phase II dose of talquetamab in patients with relapsed/refractory multiple myeloma.

Data from the phase 2 the phase 3 SWOG S1216 presented during the ASCO Annual Meeting shows numerical overall survival improvement with he experimental combination that missed the threshold for statistical significance.

Pimitespib, a heat shock protein 90 inhibitor doubled the progression-free survival and prolonged the overall survival compared with placebo in patients with advanced gastrointestinal stromal tumor that is refractory to imatinib, sunitinib, and regorafenib, according to results from the phase 3 CHAPTER-GIST-301 trial.

According to updated results presented during the 2021 ASCO Annual Meeting, teclistamab administered at the recommended phase 2 dose demonstrated encouraging safety and efficacy among patients with relapsed/refractory multiple myeloma treated in a first-in-human phase 1 trial.

The combination of alrizomadlin and pembrolizumab was well tolerated in patients with unresectable or metastatic melanoma or advanced solid tumors that have been resistant to immuno-oncologic drugs treated in a phase 2 study.

The risk of fractures in men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer was controlled by the use of bone-protecting agents during treatment with radium-223 plus enzalutamide.

A second-generation 4chimeric antigen receptor (CAR) T-cell agent has induced responses in patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated in a phase 1 study.

The combination of regorafenib and avelumab showed modest anti-tumor activity and survival rates in patients with heavily-pretreated biliary tract solid tumors.

In the phase 2 PANAMA trial, adding panitumumab to 5-fluorouracil and leucovorin showed significant improvement in progression-free survival as a maintenance treatment over 5-FU/leucovorin alone in patients with RAS wild-type metastatic colorectal cancer.

With addition 16-month follow-up, the benefit of fam-trastuzumab deruxtecan-nxki as treatment of patients with HER2-overexpressing metastatic colorectal cancer showed results that were consistent with the primary analysis of the DESTINY-CRC01 trial study.